US Top News and Analysis
Pharma major Novartis falls 9% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Shown as published in the source's RSS feed. IndiaAIFounders doesn't link out to third-party sites — this is the complete detail available from the feed itself.